Brokers Set Expectations for VTGN Q1 Earnings

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) – Stock analysts at William Blair issued their Q1 2026 EPS estimates for shares of Vistagen Therapeutics in a research note issued on Thursday, November 7th. William Blair analyst M. Minter expects that the company will earn ($0.36) per share for the quarter. William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for Vistagen Therapeutics’ current full-year earnings is ($1.85) per share. William Blair also issued estimates for Vistagen Therapeutics’ Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.35) EPS and Q4 2026 earnings at ($0.34) EPS.

Vistagen Therapeutics Stock Down 3.0 %

NASDAQ:VTGN opened at $2.93 on Monday. The stock’s fifty day moving average price is $3.07 and its two-hundred day moving average price is $3.52. Vistagen Therapeutics has a 52-week low of $2.55 and a 52-week high of $5.86.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its earnings results on Tuesday, August 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. Vistagen Therapeutics had a negative net margin of 4,521.71% and a negative return on equity of 36.35%. The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.30 million. During the same period in the prior year, the business earned ($0.94) earnings per share.

Hedge Funds Weigh In On Vistagen Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. American Century Companies Inc. grew its position in shares of Vistagen Therapeutics by 49.1% during the 2nd quarter. American Century Companies Inc. now owns 30,315 shares of the company’s stock worth $105,000 after buying an additional 9,984 shares during the period. Blair William & Co. IL increased its holdings in shares of Vistagen Therapeutics by 29.2% in the second quarter. Blair William & Co. IL now owns 88,466 shares of the company’s stock worth $308,000 after acquiring an additional 20,000 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of Vistagen Therapeutics during the 1st quarter valued at about $169,000. Valence8 US LP acquired a new stake in Vistagen Therapeutics during the 3rd quarter worth approximately $103,000. Finally, StemPoint Capital LP boosted its holdings in shares of Vistagen Therapeutics by 3.3% in the first quarter. StemPoint Capital LP now owns 1,848,582 shares of the company’s stock valued at $9,292,000 after buying an additional 58,400 shares during the period. Institutional investors own 78.39% of the company’s stock.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.